Melanoma Clinical Trial

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Summary

The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject (or legally authorized representative, where applicable) is willing and able to provide signed informed consent and can follow protocol requirements
Subject is ≥18 years of age at time of informed consent
Eastern Cooperative Oncology Group performance status of 0 or 1
Subject has documented evidence of a BRAF V600 mutation obtained from tumor tissue or liquid biopsy: (other protocol conditions may apply)

Subject must have received ≥1 prior line of SoC therapy for their unresectable locally advanced or metastatic disease with disease progression on or after last prior treatment. Prior regimens for these subjects vary by indication and investigational arm, but must have included the following:

Melanoma or NSCLC (Phase 1 and Phase 2 Arms A1 and B1): Prior receipt of a BRAF inhibitor and an immune checkpoint inhibitor (any sequence or combination). Prior (neo)adjuvant immunotherapy may be acceptable.
CRC: Subjects must have received no more than 4 lines of prior therapy which includes systemic chemotherapy-based regimen per SoC for unresectable locally advanced or metastatic disease, and previous treatment with BRAF inhibitor in combination with an EGFR monoclonal antibody. Subjects with documented MSI-H or dMMR CRC must have received prior immunotherapy. Subjects with MSS disease must have received at least 2 prior treatments. Subjects who received neo(adjuvant) chemotherapy regimens may be eligible.
ATC: Subjects must have received SoC therapy options including BRAF inhibitor if available and of benefit to the subject
Other BRAF V600 mutant solid tumors (non-CNS): Subjects must have received SoC therapy options per their Investigator's best judgment, including BRAF inhibitor if available and of benefit to the subject
Subject has measurable disease per RECIST v1.1
Adequate bone marrow, liver, renal, and cardiac function
A female subject may be eligible if not pregnant, planning a pregnancy, not breast feeding, a women of non-child bearing potential or a WOCBP willing to comply with protocol conditions relating to the use contraception, ova or blood donation and pregnancy testing prior to the first dose
A male subject must agree to comply with protocol conditions relating to the use of contraception, sperm and blood donation
Subject can safely swallow a tablet or pill

Other protocol defined exclusion criteria may apply

Exclusion Criteria:

Subject has had major surgery within 21 days prior to the planned first dose. Minor surgery is permitted within 21 days prior to enrollment
Subject with CNS involvement (primary tumor or metastatic disease), except if clinically stable, have no evidence of new or enlarging brain metastases and are on stable or tapering doses of steroids for at least 7 days prior to first dose. Subjects with untreated brain metastases may be eligible to enter without prior radiation therapy.
Subject with known malignancy other than trial indication that is progressing or has required treatment within the past 3 years, except for conditions that have undergone potentially curative therapy
Subject with history of thromboembolic or cerebrovascular events ≤6 months as defined in the protocol
Subject with impaired cardiac function or clinically significant cardiac disease, as defined in the protocol
Subject with history of uncontrolled diabetes mellitus (only for subjects who will receive CFT1946 + trametinib)
Subject with history or current evidence of retinal vein occlusion (RVO), chorioretinopathy, or current risk factors for RVO (only for subjects who will receive CFT1946 + trametinib)
Subject has received live, attenuated vaccine within 28 days prior to first dose administration
Subject has history of pneumonitis or interstitial lung disease
Subject has history of uveitis
Subject has clinically significant gastrointestinal abnormalities.
Subject has known human immunodeficiency virus (HIV) infection (with exceptions)
Subject has history of or known HBV or active HCV infection
Subject has concurrent administration of strong CYP3A4/5 inhibitors and inducers, including any herbal medications/supplements
Subject has presence of Grade ≥2 toxicity due to prior cancer therapy, excepting alopecia and hypothyroidism requiring thyroid replacement therapy
Subject has initiation or receipt of the following ≤7 days prior to first dose administration: Hematopoietic colony-stimulating growth factors, transfusion of packed red blood cells (pRBC), and transfusion of platelets
Subject is pregnant, breastfeeding, or expecting to conceive or father children any time during the study

Other protocol defined exclusion criteria may apply

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

206

Study ID:

NCT05668585

Recruitment Status:

Recruiting

Sponsor:

C4 Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

Florida Cancer Specialists
Sarasota Florida, 34232, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States
Sarah Cannon and HCA Research Institute
Nashville Tennessee, 37203, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Virginia Cancer Specialists (NEXT Oncology Virginia)
Fairfax Virginia, 22031, United States
University of Wisconsin
Madison Wisconsin, 53792, United States
Institut Bergonie
Bordeaux Cedex , 33076, France
Chu de Lille
Lille , 59037, France
Centre Leon Berard
Lyon , 69008, France
IUCT Oncopole
Toulouse , 31059, France
NEXT Oncology Barcelona
Barcelona , 08023, Spain
Hospital Universitario Vall d'Hebron
Barcelona , 08035, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jiminez Diaz
Madrid , 28040, Spain
Hospital Clinico Universitario de Valencia
Valencia , 46010, Spain

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

206

Study ID:

NCT05668585

Recruitment Status:

Recruiting

Sponsor:


C4 Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.